Cargando…

One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial

AIMS: To confirm, in a 26‐week extension study, the sustained efficacy and safety of a fixed combination of insulin degludec and liraglutide (IDegLira) compared with either insulin degludec or liraglutide alone, in patients with type 2 diabetes. METHODS: Insulin‐naïve adults with type 2 diabetes ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Zacho, M., Reiter, P. D., Buse, J. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744775/ https://www.ncbi.nlm.nih.gov/pubmed/25980900 http://dx.doi.org/10.1111/dom.12498

Ejemplares similares

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
por: Rodbard, H. W., et al.
Publicado: (2016)

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
por: Mathieu, Chantal, et al.
Publicado: (2013)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
por: Linjawi, Sultan, et al.
Publicado: (2016)

OR14-2 Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial
por: Dandona, Paresh, et al.
Publicado: (2019)

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
por: Meneghini, Luigi, et al.
Publicado: (2013)

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial
por: Onishi, Yukiko, et al.
Publicado: (2013)

COVID-19 in a 26-week preterm neonate
por: Piersigilli, Fiammetta, et al.
Publicado: (2020)

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice
por: Sesti, Giorgio, et al.
Publicado: (2020)

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
por: Harris, Stewart, et al.
Publicado: (2020)

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Intrauterine Intervention of Pulmonary Atresia at 26(th) Gestational Week
por: Xing, Quan-Sheng, et al.
Publicado: (2018)

Healthy and Safe Swimming Week — May 20–26, 2019
Publicado: (2019)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Efficacy and safety of once‐daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26‐week, treat‐to‐target trial
por: Kadowaki, Takashi, et al.
Publicado: (2016)

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test
por: Holst, Jens J., et al.
Publicado: (2015)

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
por: Jensen, Jacob K., et al.
Publicado: (2021)

FCC week 2019 - 26.07.2019 (3rd day)
por: Lobet, Nicolas
Publicado: (2019)

Safety of torasemide in healthy adult dogs administered daily for 26 weeks
por: Coussanes, Evelyne, et al.
Publicado: (2021)

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial
por: Hirsch, Irl B., et al.
Publicado: (2012)

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial
por: Bailey, T. S., et al.
Publicado: (2016)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
por: Miyagawa, J., et al.
Publicado: (2015)

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
por: Ericsson, Åsa, et al.
Publicado: (2017)

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial (BEGIN: ADD TO GLP‐1 Study)
por: Aroda, V. R., et al.
Publicado: (2016)

ATLAS liquid argon week in Dresden 26.09-30.09.2016
Publicado: (2016)

Recreational Water Illness and Injury Prevention Week — May 20–26, 2013
Publicado: (2013)

Vital Statistics, &c., for Four Weeks Ended 26th July, 1930
por: Macgregor, A. S. M.
Publicado: (1930)

Vital Statistics, &c., for Four Weeks Ended 26th June, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 26th March, 1927
por: Macgregor, A. S. M.
Publicado: (1927)

Vital Statistics, &c., for Four Weeks Ended 26th February, 1927
por: Macgregor, A. S. M.
Publicado: (1927)

Vital Statistics. &c., for Four Weeks Ended 26th December, 1925
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 26th November, 1927
por: Macgregor, A. S. M.
Publicado: (1927)

Vital Statistics, &c., for Four Weeks Ended 26th May, 1928
por: Macgregor, A. S. M.
Publicado: (1928)

Vital Statistics, &c., for Four Weeks Ended 26th January, 1929
por: Macgregor, A. S. M.
Publicado: (1929)

Vital Statistics, &c., for Four Weeks Ended 26th October, 1929
por: Macgregor, A. S. M.
Publicado: (1929)

Vital Statistics, &c., for Four Weeks Ended 26th January, 1935
por: Macgregor, A. S. M.
Publicado: (1935)

Vital Statistics, &c., for Four Weeks Ended 26th March, 1932
por: Macgregor, A. S. M.
Publicado: (1932)

Cannot write session to /tmp/vufind_sessions/sess_mjiaik2mnfvb3e99i57iigld2f